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Background:This phase III trial compared the efﬁcacy and safety of gemcitabine plus capecitabine (GemCap) versus single-agent
gemcitabine (Gem) in advanced pancreatic cancer as ﬁrst-line chemotherapy.
Methods: A total of 214 advanced pancreatic cancer patients were enrolled from 16 hospitals in South Korea between 2007 and
2011. Patients were randomly assigned to receive GemCap (oral capecitabine 1660mg/m2 plus Gem 1000mg/m2 by 30-minute
intravenous infusion weekly for 3 weeks followed by a 1-week break every 4 weeks) or Gem (by 30-minute intravenous infusion
weekly for 3 weeks every 4 weeks).
Results: Median overall survival (OS) time, the primary end point, was 10.3 and 7.5 months in the GemCap and Gem arms,
respectively (P=0.06). Progression-free survival was 6.2 and 5.3 months in the GemCap and Gem arms, respectively (P=0.08).
GemCap signiﬁcantly improved overall response rate compared with Gem alone (43.7% vs 17.6%; P=0.001). Overall frequency of
grade 3 or 4 toxicities was similar in each group. Neutropenia was the most frequent grade 3 or 4 toxicity in both groups.
Conclusion: GemCap failed to improve OS at a statistically signiﬁcant level compared to Gem treatment. This study showed a
trend toward improved OS compared to Gem alone. GemCap and Gem both exhibited similar safety proﬁles.
Abbreviations: BSA = body surface area, CA 19-9 = carbohydrate antigen 19-9, Cap = capecitabine, CEA = chorioembryonic
antigen, CR = complete responses, CT = computed tomography, ECOG = Eastern Cooperative Oncology Group, FOLFIRINOX =
ﬂuorouracil, irinotecan, oxaliplatin, and leucovorin, FU= ﬂuorouracil, Gem = gemcitabine, GemCap = gemcitabine plus capecitabine,
HR = hazard ratio, MRI = magnetic resonance imaging, ORR = objective response rate, OS = overall survival, PET = positron
emission tomography, PFS = progression-free survival, PR = partial responses, RECIST = response evaluation criteria in solid
tumors.
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Figure 1. Study population assigned to treatment from 16 hospitals. For the
statistical analysis, we ﬁnally selected 214 patients with pancreatic cancer who
received GemCap chemotherapy or Gem chemotherapy alone. Gem =
gemcitabine, GemCap = gemcitabine plus capecitabine.Pancreatic cancer is the fourth leading cause of cancer death in
the United States[1] and is still one of the most lethal malignancies
with a 5-year survival of only 5%.[2] In South Korea,
approximately 5400 people develop exocrine pancreatic cancer
each year, and the majority of patients present with inoperable
advanced pancreatic cancer at the time of diagnosis.[3,4]
Gemcitabine (Gem) has been administered as a standard single-
agent therapy for the treatment of advanced pancreatic cancer,
with signiﬁcant survival beneﬁt compared with 5-ﬂuorouracil (5-
FU).[5] Recently, the combination of ﬂuorouracil, irinotecan,
oxaliplatin, and leucovorin (FOLFIRINOX) and gemcitabine
plus albumin bound paclitaxel particles have been associated
with a signiﬁcant improvement in overall survival (OS).[6,7]
However, owing to their greater toxicity, adoption of these
treatment regimens is considered for patients with good
performance status who do not have coexisting conditions.[8,9]
Capecitabine (Cap) is an orally administered, tumor-selective
ﬂuoropyrimidine carbamate that can be incorporated into
schedules that provide prolonged ﬂuorouracil exposure at lower
peak concentrations, thus simulating continuous infusion of
ﬂuorouracil. Cap has a different mechanism of action than Gem
with no overlapping toxicities. In addition, orally administered
Cap chemotherapy is more convenient than intravenously
administered 5-FU. The improved tolerability and similar efﬁcacy
of Cap compared with intravenous FU, and the convenience of
oral administration make Cap an attractive treatment option in
various other cancers.[10,11]
Recent advances in the management of advanced pancreatic
cancer include 2 randomized phase III clinical trials indicating a
response beneﬁt associated with GemCap combination chemo-
therapy compared with Gem monotherapy.[10,11] Cunningham
et al[11] reported that GemCap chemotherapy signiﬁcantly
improved the objective response rate (ORR) and was associated
with a trend toward improved OS (hazard ratio [HR], 0.86; P=
0.08) as compared with treatment by Gem alone. Until now, no
phase III study has been conducted to evaluate the efﬁcacy of
GemCap chemotherapy in an Asian patient population. To our
knowledge, this study is the ﬁrst phase III study conducted in an
Asian patient population with advanced pancreatic cancer aimed
at evaluating the efﬁcacy and safety of GemCap combination
therapy compared with Gem monotherapy.
2. Materials and methods
2.1. Patients
A total of 214 advanced pancreatic cancer patients were enrolled
from 16 hospitals in South Korea between 2007 and 2011.
Patients were randomly assigned to GemCap or Gem treatment
groups (Fig. 1). The eligibility of patients was conﬁrmed
histologically or with computed tomography (CT), magnetic
resonance imaging (MRI), and positron emission tomography
(PET) imaging. The inclusion criteria were inoperable locally
advanced or metastatic pancreatic cancer according to the
national comprehensive cancer network guidelines,[9] no prior
history of chemotherapy or radiotherapy, between the ages of 18
and 85 years, Eastern Cooperative Oncology Group (ECOG)
performance status of 0 to 2, and adequate bone marrow,
hepatic, and renal function. Exclusion criteria were pancreatic
cancer other than adenocarcinoma, concurrent malignancy,
brain metastasis, serious uncontrollable medical conditions, and
signiﬁcant cardiac history. The study protocol conformed to the2recruited patients signed a written consent form before inclusion
to the study. The present study is not registered in a clinical trials
registry, since the present study was initiated before this became
standard practice in South Korea.
2.2. Study protocol
This study was a multicenter, randomized, phase III trial with OS
as the primary endpoint, conducted in Asian patients with
advanced pancreatic cancer. Secondary endpoints were progres-
sion-free survival (PFS), ORR, disease control rate, and toxicity.
We randomly assigned eligible patients to each treatment arm on
a 1:1 basis according to a computer-generated variable-size
blocked randomizationmethod. Randomization was stratiﬁed by
extent of disease (locally advanced stage vs metastatic stage).
GemCap arm received oral capecitabine 1660mg/m2 daily for
3 weeks followed by a 1-week break plus Gem 1000mg/m2 by
30-minute intravenous infusion weekly for 3 weeks every 4
weeks. Gem arm received 30-minute intravenous infusion weekly
for 3 weeks every 4 weeks. The body surface area (BSA) was
recalculated and the dose levels of GemCap were adjusted based
on the recalculated BSA prior to each cycle. This treatment was
continued until response evaluation criteria in solid tumors
(RECIST)-deﬁned progressive disease and cumulative toxic
effects were developed, or if the patients chose to discontinue
the treatment.[12] A research nurse or doctor in every center
checked the toxicities of the registered medication in this study.
Regarding the follow-up schedule, all patients were administered
treatment on days 1, 8, and 15 every 4 weeks in subsequent
cycles. During hospitalization, all patients’ vital sign, laboratory
results, and general condition were investigated. After discharge
from hospital, all patients were followed up within 1 to 2 weeks
to check their general condition.2.3. Response evaluation
TheORRwas deﬁned as the proportion of patients with complete
responses (CR) and partial responses (PR) as measured by spiral
CT. OS was calculated from the date of diagnosis to the date of
death. The response to treatment was evaluated by CT or MRI
after every 2 cycles of chemotherapy were completed. The
objective tumor response was evaluated according to the RECIST
Table 1
Baseline characteristics of patients.
Gem n=106 GemCap n=108 P value
Age 64 (43–85) 64 (37–80) 0.354
Sex
Male 57 (53.8) 63 (58.3) 0.458
Female 49 (46.2) 45 (41.7)
Hb 11.9±1.8 12.3±1.6 0.099
WBC 7382±2707 8675±11272 0.252
AST 44±57 37±42 0.376
ALT 60±97 49±79 0.348
ALP 266±315 257±270 0.826
T.bil 2.5±6.9 1.9±4.0 0.395
Albumin 3.9±0.5 3.9±0.5 0.657
CA 19-9 9102±59,833 1705±3299 0.241
ECOG
0 to 1 88 (83.0) 98 (90.7) 0.094
2 to 3 18 (17.0) 10 (9.3)
Pain (0–100)
<50 86 (81.1) 90 (83.3) 0.674
≥50 20 (18.9) 18 (16.7)
Analgesic
No use 34 (32.1) 39 (36.1) 0.778
Nonopioid 13 (12.3) 14 (13.0)
Opioid 59 (55.7) 55 (50.9)
Stage
II 10 (9.4) 6 (5.6) 0.536
III 20 (18.9) 23 (21.3)
Lee et al. Medicine (2017) 96:1 www.md-journal.comcriteria (version 1.1). The levels of carbohydrate antigen (CA) 19-
9 and chorioembryonic antigen (CEA) were measured at the end
of every 2 cycles. Toxicities were evaluated according to the
National Cancer Institute Common Toxicity Criteria, version
4.0.[13]
2.4. Statistical analysis
The sample size was estimated based on the hypothesis that the
GemCap combination therapywould increase themedianOS time
by 2 months compared with single-agent Gem (overall type I error
possibility, alpha of 0.05 and power of 90%).[10] The calculated
sample sizewas 178 patients (89 patients per group). The 1 interim
analysis was performed after observing approximately 124 (one-
half) events. Statistical considerationswere reviewed anddiscussed
with Department of Biostatistics in Yonsei University College of
Medicine. Data was expressed as mean± standard deviation, n
(%), orn, as appropriate.Variableswere comparedusing thex2 test
for categorical data and Student t test for continuous variables to
evaluate statistical signiﬁcance of the differences in baseline
characteristics between groups. Both OS and PFS estimates were
calculatedusing theKaplan–Meiermethod, and the survival curves
were compared between treatment arms using the log-rank test. A
P value of<0.05was considered to indicate statistical signiﬁcance.
Statistical analyses were performed using SPSS version 18.0 (SPSS,
Chicago, IL).IV 76 (71.7) 79 (73.1)
Tumor location
Head 42 (39.6) 46 (42.6) 0.547
Body 26 (24.5) 21 (19.4)
Tail 25 (23.6) 31 (28.7)
Diffuse 13 (12.3) 9 (8.3)
Variables are expressed as the mean±SD or n (%).
ALP= alkaline phosphatase, ALT=alanine transaminase, AST= aspartate transaminase, CA 19-9=
carbohydrate antigen 19-9, ECOG=Eastern Cooperative Oncology Group performance status, Gem=
gemcitabine, GemCap=gemcitabine plus capecitabine, Hb=hemoglobin, T.bil= total bilirubin,
WBC=white blood cell.3. Results
3.1. Patient characteristics
The Median age was 54 years (range, 37–85 years) and the
gender distribution was 120 men and 94 women. Patients were
randomly allocated to Gem (n=106) and GemCap (n=108)
groups. Ten (4.6%) patients were ineligible because of loss to
follow-up or dropout from the study. These patients were
included in the analyses on an intention-to-treat basis. Patient
characteristics are shown in Table 1. Variables were well
balanced between 2 groups.3.2. Overall survival and progression-free survival
GemCapwas associated with a trend toward better OS compared
with Gem alone (HR, 0.82; 95% CI, 0.67–1.01; P=0.06). The
median OS times for patients in GemCap and Gem treatment
groups were 10.3 and 7.5 months, respectively. GemCap did notGEM
GEM-CAP
Log rank  P = 0.06
A
Figure 2. Kaplan–Meier overall survival curves and progression-free survival curve
end point, was 10.3 and 7.5 months in the GemCap and Gem arm, respectively
GemCap and Gem arm, respectively (P=0.08). Gem = gemcitabine, GemCap =
3show a signiﬁcantly improved PFS compared with Gem (HR,
0.87; 95% CI, 0.73–1.03; P=0.08). The median PFS for
GemCap was 6.2 months, and that for Gem was 5.3 months.
The OS and PFS by treatment arm are indicated in Fig. 2. On
subgroup analysis according to ECOG and age, there was no
signiﬁcant survival difference between the 2 groups (Fig. 3 and
Supplementary ﬁgure, http://links.lww.com/MD/B477).GEM
GEM-CAP
Log rank  P = 0.08
B
s in pancreatic cancer patients. A, Median overall survival (OS) time, the primary
(P=0.06). B, Progression-free survival (PFS) was 6.2 and 5.3 months in the
gemcitabine plus capecitabine.
GEM
GEM-CAP
Log rank  P = 0.202
GEM
GEM-CAP
Log rank  P = 0.162
Overall survival, ECOG 0~1 Overall 
A B
C D
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Figure 3. Kaplan–Meier overall survival curves and progression-free survival curves in patients according to performance status. Subanalysis in patients with good
performance status did not show a signiﬁcant prolongation of median OS time and PFS time in the GemCap arm compared with Gem arm. Gem = gemcitabine,
GemCap = gemcitabine plus capecitabine, OS = overall survival, PFS = progression free survival.
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Patients randomly assigned to GemCap treatment group had a
signiﬁcantly improved ORR over those assigned to Gem (43.7%
vs 17.6%, respectively; P=0.001). The efﬁcacies of the treat-
ments are summarized in Table 2. Of the total 214 patients, none
exhibited CR, 54 (25.2%) exhibited PR, and 58 (27.1%) were
observed to have stable disease. Progressive disease occurred in
the 66 patients (30.8%).Table 2
Response rates according to RECIST criteria.
Gem (n=106) GemCap (n=108) P value
Response rate
CR 0 0 (0) 0.001
PR 16 (17.6) 38 (43.7)
SD 33 (36.3) 25 (28.7)
PD 42 (46.2) 24 (27.6)
Overall RR 16 (17.6) 38 (43.7)
Progression-free survival
Median 5.3 6.2 0.08
95% CI 3.91–6.68 5.11–7.28
Overall survival
Median 7.5 10.3 0.06
95% CI 6.22–8.77 7.94–12.65
Variables are expressed as n (%).
CI= conﬁdence interval, CR= complete response, Gem=gemcitabine, GemCap=gemcitabine plus
capecitabine, PD=disease progression, PR=partial response, RECIST= response evaluation criteria
in solid tumors, RR= response rate, SD= stable disease.
43.4. Toxicities
Therapy-related toxicities were monitored in all 204 patients who
were treated with 1000mg/m2 Gem or 1660mg/m2 of oral Cap.
Both treatment arms were well tolerated. Table 3 summarizes the
grade 3 or 4 toxicities associated with the treatment arms. The
overall frequency of grade 3 or 4 toxicities was similar in each
group. Neutropenia was the most frequently observed grade 3 or
4 toxicity in both groups (29.2%). Although GemCap treatment
resulted in increased neutropenia compared with Gem treatment,
febrile neutropenia was not observed more than Gem treatment.
The frequencies of other adverse events such as nausea, vomiting,
diarrhea, and stomatitis were similar between the 2 arms.Table 3
Grade 3 or 4 adverse events.
Adverse event Gem (n=101) GemCap (n=103)
Anemia 4 (3.9) 5 (4.8)
Neutropenia 12 (11.8) 18 (17.4%)
Thrombocytopenia 5 (4.9) 1 (0.9)
Febrile neutropenia 1 (1) 1 (0.9)
Nausea/vomiting 3 (2.9) 5 (4.8)
Diarrhea 0 (0) 2 (1.9)
Stomatitis 0 (0) 4 (3.8)
Hand-foot syndrome 0 (0) 1 (0.9)
General weakness 3 (2.9) 1 (0.9)
Variables are expressed as n (%).
Gem=gemcitabine, GemCap=gemcitabine plus capecitabine.
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This study did not show the statistical OS improvement in
GemCap compared with Gem treatment in advanced pancreatic
cancer patients. However, a trend toward improved OS in
patients treated with GemCap was observed. This study also
showed that advanced pancreatic cancer patients responded
better to GemCap with acceptable levels of adverse events.
Pancreatic cancer remains as one of the most common and
lethal cancers. FU-based chemotherapy was known to improve
overall survival by approximately 3 months compared with best
supportive care alone.[8] In 1997, a study comparing Gem with
FU in patients with advanced pancreatic cancer showed an
improved overall survival of 1 month among patients receiving
Gem.[5] Over the next 10 years, multiple randomized studies
comparing single-agent Gem with combination chemotherapy
have been conducted showing no effective improvement in
survival.[14–17] Exceptionally, the incorporation of erlotinib, an
EGFR inhibitor, resulted in a signiﬁcant improvement of the
overall survival by approximately 2 weeks (HR 0.82, P=0.038,
median 6.2 vs 5.9 months, respectively). However, owing to its
limited effect and added toxicity, this treatment regimen has not
been frequently adopted.[18]
Two recently conducted clinical trials showed prolonged overall
survival of approximately 1 year in advanced pancreatic cancer
patients. In theﬁrst study,more recent treatment regimens including
FOLFIRINOX were associated with a signiﬁcant improvement in
median OS compared with Gemmonotherapy (11.1 months vs 6.8
months, respectively; P<0.001).[7] In the second study, Gem plus
nanoparticle albumin bound-paclitaxel was also associated with a
prolonged OS compared with Gem monotherapy (8.5 months vs
6.7 months, respectively; P<0.001).[6] At present, these regimens
are considered standard treatment for patients with good PS.
However, treatment-related adverse events were also worsened
with these regimens compared with Gem monotherapy, including
grade3/4neutropenia (45.7%and38%, respectively), anddiarrhea
(12.7% and 6%, respectively).
Therefore, alternative combination chemotherapeutic regi-
mens have been studied for the treatment of patients with
advanced pancreatic cancer. Among them, GemCap was
identiﬁed as an alternative combination therapy for patients
with advanced pancreatic cancer.[19,20] In a randomized phase III
trial, Cunningham et al[11] showed a signiﬁcant improvement in
the PFS (HR, 0.78; 95% CI, 0.66–0.93; P=0.004) and a trend
towards improved OS (HR, 0.86; 95% CI, 0.72–1.02; P=0.08)
in patients receiving GemCap therapy compared with those
receiving Gemmonotherapy. In the study, Cunningham et al used
intensive dose-combination regimen compared with another
phase III trial (oral capecitabine 1660 vs 650mg/m2/day;
gemcitabine infusion on days 1, 8, and 15, every 4 weeks vs 1
and 8, every 3 weeks) and intensive dose-combination showed
more effective results than another regimen.[10,11] Using high
dose of chemotherapy regimens, the present study of GemCap
combination therapy produced signiﬁcantly improved ORR of
43.7% and a median PFS of 6.2 months, respectively. These
results were similar to previous phase II studies conducted in
South Korea.[20]
To our knowledge, this study investigating the use of GemCap
combination therapy for the treatment of advanced pancreatic
cancer was a ﬁrst in Asia. In this study, a longer OS of 10.3
months compared with previous phase III studies is reported.
This is associated with the recent improvements in cancer
supportive care such as pain control, complication control, and5nutritional support. This data was also in agreement with
previous phase II study data (10.3 months vs 10 months,
respectively).[20]
There are some limitations in the study. We failed to show the
signiﬁcant difference in overall survival between GemCap and
Gem due to an insufﬁcient number of enrolled patients differing
from the initially planned number. South Korea has universal
health insurance system that covers almost the entire population.
The medical insurance system of government did not cover the
use of gemcitabine plus capecitabine on pancreatic cancer during
the present study period. We could not prescribe additive
gemcitabine plus capecitabine chemotherapy in patients with
pancreatic cancer. And as a result, we did not enroll the sufﬁcient
number of patients during the study period. However, we showed
a trend towards improved OS in patients who received GemCap
although this was not statistically signiﬁcant. Furthermore,
response rates were signiﬁcantly higher in GemCap patients
compared with Gem (43.7% vs 17.6%, respectively). Second, the
results from the new trials such as Von Hoff et al[6] about the
increased survival in pancreatic cancer were published in 2013.
Unfortunately, it decreases the value and novelty of the results
from the current study. However, there was no phase III study
that has been conducted to evaluate the efﬁcacy of GemCap
chemotherapy in an Asian patient population until now.
Recently, many novel biological agents targeting pancreatic
cancer and its microenvironment have been reported to be
promising in preclinical investigations and phase I/II clinical
studies.[21–24] However, an effective therapeutic agent for the
treatment of pancreatic cancer does not exist presently. Depend-
ing on patients’ health conditions, conventional chemotherapeu-
tic agents are still administered.
In conclusion, this study was the ﬁrst phase III study conducted
in Asian patients using GemCap combination therapy. GemCap
combination did not show statistically signiﬁcant survival beneﬁt
compared with Gem treatment. There was a trend toward
improved OS and better response in pancreatic cancer patients
treated with GemCap.
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